From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2018 call → NOWe need to determine if management describes a recent transition into an approved/specified/listed status that will bring future business without discrete selling events, and that this is new enough that most volume is ahead. Scan transcript for relevant statements. Leroy Ball mentions: "Our major box store has recently made the decision to convert their ground contact treated wood program from a soluble copper based product to our patented technology microprobe [ph]. The transition is planned to occur late this fall and while it will have little effect on the balance of 2018, it should provide a nice boost heading into 2019 whether it be through unit sales or product or increase royalty payments." This sounds like a customer (major box store) converting to their patented technology. That could be a specification or approved product? But it's a single customer decision, not necessarily a buyer-side system like a formulary or approved supplier list. Also, it's planned to occur late this fall, so it's pending, not yet in effect. The transcript says "planned to occur" - so it's not yet achieved. Also, "little effect on the balance of 2018" but boost heading into 2019. However, the status is not yet in place; it's planned. The question requires that the status is recent and the flow is only beginning. Here it's future. Also, it's a single customer conversion, not a systemic listing. The question asks about being placed into a buyer's purchasing system. This is a customer decision to adopt a product, but it's still a discrete sale? Actually, if a major box store converts their program to a specific product, that might mean the product becomes the standard for that program, so future orders come without re-arguing. But it's not yet happened. The transcript says "planned to occur late this fall" - so it's pending. The answer should be NO because it's not yet achieved. Also, there is mention of "sizable new international account" that they hope to talk about next call - that's also pending. No other mention of approved supplier lists, formularies, etc. The company's business seems to be selling products to customers, not being placed into a system. The only possible is the box store conversion, but it's future and not yet in effect. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.